AVITA Medical, Inc. (RCEL)
12.72
+0.71
(+5.91%)
USD |
NASDAQ |
Oct 02, 16:00
12.66
-0.06
(-0.51%)
After-Hours: 20:00
AVITA Medical EPS Diluted (Quarterly) : -0.2492 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.2492 |
| March 31, 2026 | -0.3474 |
| December 31, 2025 | -0.3825 |
| September 30, 2025 | -0.4644 |
| June 30, 2025 | -0.3762 |
| March 31, 2025 | -0.5279 |
| December 31, 2024 | -0.4432 |
| September 30, 2024 | -0.6236 |
| June 30, 2024 | -0.5976 |
| March 31, 2024 | -0.7277 |
| December 31, 2023 | -0.2773 |
| September 30, 2023 | -0.343 |
| June 30, 2023 | -0.4114 |
| March 31, 2023 | -0.3658 |
| December 31, 2022 | -0.2134 |
| September 30, 2022 | -0.2235 |
| June 30, 2022 | -0.2507 |
| March 31, 2022 | -0.3795 |
| June 30, 2021 | -0.1898 |
| March 31, 2021 | -0.2638 |
| December 31, 2020 | -0.2609 |
| September 30, 2020 | -0.4756 |
| June 30, 2020 | -0.6042 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| Date | Value |
|---|---|
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
| December 31, 2013 | 0.00 |
| September 30, 2013 | 0.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Halozyme Therapeutics, Inc. | 1.897 |
| Iovance Biotherapeutics, Inc. | -0.1051 |
| Amgen, Inc. | 4.366 |
| Editas Medicine, Inc. | -0.1528 |
| Arcus Biosciences, Inc. | -0.7216 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -7.663M |
| Revenue (Quarterly) | 21.70M |
| Total Expenses (Quarterly) | 29.36M |
| Enterprise Value | 430.73M |
| Gross Profit Margin (Quarterly) | 81.87% |
| Profit Margin (Quarterly) | -35.31% |
| Earnings Yield | -11.35% |
| Normalized Earnings Yield | -11.71 |